EMA Application withdrawn: Oportuzumab monatox DLRC Pharma Services (oportuzumab monatox) — DLRC Pharma Services Ltd

View source ↗

Summary

The EMA has withdrawn the application for oportuzumab monatox, submitted by DLRC Pharma Services Ltd, for urologic and urinary bladder neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urinary Bladder Neoplasms
• Urologic Neoplasms

Drugs mentioned

• oportuzumab monatox (oportuzumab monatox)

Snippet

Status: Application withdrawn. Therapeutic area: Urologic Neoplasms;Urinary Bladder Neoplasms. MAH: DLRC Pharma Services Ltd